DR. LAL PATH LABS LTD.

Dr. Lal Path Labs Ltd. (LALPATHLAB) is a mid-cap Healthcare company valued at ₹31,218 crore operating in Healthcare Service Provider on the NSE and BSE.

Recent price move

Dr. Lal Path Labs Ltd. last traded at ₹1,894.2, modestly up 0.48% on the day.

Recent developments

On 2026-09-24, Dr Lal PathLabs announced it would acquire a 70% stake in genomics firm SN Genelab for up to ₹168 crore, leading to a 1.88% rise in its share price. On 2026-07-24, the company reported Q1 results with net profit rising 29% YoY and declared an interim dividend. On 2026-09-17, the company previewed its Q2 results, focusing on revenue and margins.

Financial performance

The company's business is improving, with annual revenue rising 12.3% and annual net profit growing 3.6%. The latest quarter saw revenue rise 19.1% and net profit jump 27.2% compared to the same quarter a year earlier, though the net profit margin narrowed 1.5 percentage points to 18.5%.

Valuation multiples

The stock trades at 62.6 times earnings, a premium to the Healthcare median of 32.0, 12.83 times book value. It yields 0.3%.

Things to watch

The stock is 5.2% below its 52-week high. The net profit margin has narrowed 1.5 percentage points to 18.5%. Promoter holding remains at 53.19%, with no significant changes reported.

Where it stands

The company's latest quarter showed strong growth in both revenue and net profit, with the latter rising 27.2% compared to the same quarter a year earlier. The stock is 5.2% below its 52-week high.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.